Document is current
Any future updates will be listed below
-
Authors
Ali Babar, Barkat
Vu, Mai
Koponen, Marjaana
Taipale, Heidi
Tanskanen, Antti
Kettunen, Raimo
Tiihonen, Miia
Hartikainen, Sirpa
Tolppanen, Anna-Maija
-
Funding
Funding for this research was provided by:
Academy of Finland (295334, 307232, 327152, 295334, 307232, 327152, 295334, 307232, 327152)
- License Information
-
More Information
Article History
Received: 10 September 2021
Accepted: 18 May 2022
First Online: 28 May 2022
Declarations
:
: Register maintainers have approved the MEDALZ study plan. Data were pseudonymized before submission to the research team and study participants were not contacted. Therefore, according to Finnish legislation (including Personal Data Act 23/1999, Act on the Openness of Government Activities 621/1999 and Act on the Secondary Use of Health and Social Data 552/2019 (and previous Act on the National Health Care registers, not official English Translation as this is not available 556/1989) the study has been granted an exemption from requiring ethics approval or informed consent. Further, all the methods were performed in accordance with relevant guidelines and regulation.
: Not applicable.
: BB, MV, MK, RK, MT and AMT have no competing interests to declare. SH has received lecture fees from Astellas Pharma. HT and AT have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. HT reports personal fees from Janssen-Cilag and Otsuka.
